Lung transplantation in Hong Kong: 12 years of experience

Abstract

In addition to the usual complications there were two cases of early pulmonary tuberculosis and one rare case of delayed fungal sternotomy infection. The 1-year, 3-year and 5-year survival rates were 100%, 100% and 76.2%, respectively. All fatalities were related to the consequences of chronic rejection or its treatment. Conclusions: Despite the limited experience and the small case volume, the survival of patients was good and comparable with international experience.

Mycobacterium tuberculosis after solid organ transplantation: A review of more than 2000 cases

“…The median age, based on case reports and the single cohort, was 50 (range, 31‐68) and 51 years, respectively. Only 4 of 7 reported use of CSA, and only 1 of 3 case reports specifically mentioned use of CD4‐depleting agents . Acute rejection was reported in 4 of 6 patients …”

“…Twenty‐three cases of donor‐derived TB (DDTB) were identified (Table ) . Thirteen (56.52%) were proven by molecular analysis.…”

Donor derived Mycobacterium tuberculosis infection after solid‐organ transplantation: A comprehensive review

“…Through December 2016, a total of 22 case reports, 2 case series and 1 cohort reported on 36 cases of proven (n = 17), probable (n = 8), and possible (n = 11) DDTB cases among 16 lung, 13 kidney, 6 liver, and 1 heart recipient.…”

Talaromyces (Penicillium) marneffei infection in non-HIV-infected patients

“…85 The first HSCT was performed in 1990, and the first liver and lung transplantations were performed in 1991 and 1995, respectively. 86 , 87 , 88 Furthermore, renal transplantation has consistently remained as one of the most common types of solid organ transplantation performed each year in Hong Kong over the past few decades. While HSCT recipients are generally considered to have more severe immunosuppression and thus higher risk of developing invasive fungal infections than solid organ transplantation recipients, they tend to receive more potent and prolonged antifungal prophylaxis and/or empirical antifungal treatment with activities against T. marneffei , such as itraconazole, voriconazole, posaconazole and amphotericin B.…”